Loading…
Reported covered position: Legislative Aid to Congressman Vic Snyder (AR-02) 2002-2003; Senior Legislative Assistant & Communications Director to Congresswoman Darlene Hooley (OR-05); Executive Director, New Democrat Coalition, 2007-2008.
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2026 · third_quarter · Q3
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
Issues related to Sec. 232 pharmaceutical tariffs, onshoring active pharmaceutical ingredients (API), and supply chain disruptions for products related to the opioid public health emergency.
Source: Senate LDA
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
New Era of Preventing End-Stage Kidney Disease Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
New Era of Preventing End-Stage Kidney Disease Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
New Era of Preventing End-Stage Kidney Disease Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals; Issues regarding the One Big Beautiful Bill Act (PL 119-21).
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals; Issues regarding the One Big Beautiful Bill Act (PL 119-21).
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R.1227/S.475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals; Issues regarding the One Big Beautiful Bill Act (PL 119-21).
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R.1227/S.475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals; Issues regarding the One Big Beautiful Bill Act (PL 119-21).
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, S.864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, S.864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (S.864); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, S.864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
American Innovation and R&D Competitiveness Act of 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits, American Innovation and R&D Competitiveness Act (H.R. 2673) and American Innovation and Jobs Act (S. 866)
BIOSECURE Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act.
BIOSECURE Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Implementation of P.L. 117-169 provisions related to Medicare prescription drugs; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
McIntire-Stennis Act District of Columbia Equality Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R.7421/S.3832 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning.
McIntire-Stennis Act District of Columbia Equality Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R.7421/S.3832 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; Genetic kidney disease, including APOL-1; Ex-US access to innovative medicines; Cystic Fibrosis; Sickle cell disease.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Access to non-opioids in DoD/Tricare (H.R.8774/S.4921 - Department of Defense Appropriations Act, 2025); Access to non-opioids in VHA and general support for clinical trial operations at VHA to address high prevalence diseases and conditions (H.R.8580/S.4677 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025); Access to non-opioids for Medicare beneficiaries and education about risk of kidney disease amongst minority populations (H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025).
Department of Defense Appropriations Act, 2025
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Access to non-opioids in DoD/Tricare (H.R.8774/S.4921 - Department of Defense Appropriations Act, 2025); Access to non-opioids in VHA and general support for clinical trial operations at VHA to address high prevalence diseases and conditions (H.R.8580/S.4677 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025); Access to non-opioids for Medicare beneficiaries and education about risk of kidney disease amongst minority populations (H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Access to non-opioids in DoD/Tricare (H.R.8774/S.4921 - Department of Defense Appropriations Act, 2025); Access to non-opioids in VHA and general support for clinical trial operations at VHA to address high prevalence diseases and conditions (H.R.8580/S.4677 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025); Access to non-opioids for Medicare beneficiaries and education about risk of kidney disease amongst minority populations (H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025).
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; Genetic kidney disease, including APOL-1; Ex-US access to innovative medicines; Cystic Fibrosis; Sickle cell disease.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R.7421/S.3832 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Implementation of P.L. 117-169 provisions related to Medicare prescription drugs; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R.7421/S.3832 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease.
Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Access to non-opioids in DoD/Tricare (H.R.8774/S.4921 - Department of Defense Appropriations Act, 2025); Access to non-opioids in VHA and general support for clinical trial operations at VHA to address high prevalence diseases and conditions (H.R.8580/S.4677 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025); Access to non-opioids for Medicare beneficiaries and education about risk of kidney disease amongst minority populations (H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025).
Department of Defense Appropriations Act, 2025
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Access to non-opioids in DoD/Tricare (H.R.8774/S.4921 - Department of Defense Appropriations Act, 2025); Access to non-opioids in VHA and general support for clinical trial operations at VHA to address high prevalence diseases and conditions (H.R.8580/S.4677 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025); Access to non-opioids for Medicare beneficiaries and education about risk of kidney disease amongst minority populations (H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Access to non-opioids in DoD/Tricare (H.R.8774/S.4921 - Department of Defense Appropriations Act, 2025); Access to non-opioids in VHA and general support for clinical trial operations at VHA to address high prevalence diseases and conditions (H.R.8580/S.4677 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025); Access to non-opioids for Medicare beneficiaries and education about risk of kidney disease amongst minority populations (H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025).
American Innovation and Jobs Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits, American Innovation and R&D Competitiveness Act (H.R. 2673) and American Innovation and Jobs Act (S. 866)
American Innovation and R&D Competitiveness Act of 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits, American Innovation and R&D Competitiveness Act (H.R. 2673) and American Innovation and Jobs Act (S. 866)
American Innovation and R&D Competitiveness Act of 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits, American Innovation and R&D Competitiveness Act (H.R. 2673) and American Innovation and Jobs Act (S. 866)
American Innovation and R&D Competitiveness Act of 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits, American Innovation and R&D Competitiveness Act (H.R. 2673) and American Innovation and Jobs Act (S. 866)
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (HR 830, S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (HR 830, S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
American Innovation and Jobs Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits, American Innovation and R&D Competitiveness Act (H.R. 2673) and American Innovation and Jobs Act (S. 866)
American Innovation and Jobs Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits, American Innovation and R&D Competitiveness Act (H.R. 2673) and American Innovation and Jobs Act (S. 866)
American Innovation and Jobs Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits, American Innovation and R&D Competitiveness Act (H.R. 2673) and American Innovation and Jobs Act (S. 866)
PSA Screening for HIM Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing, health care cost and price transparency: HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act"; H.R.5801 - HELP Copays Act.
Consolidated Appropriations Act, 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; S .586/H.R.3259 - NOPAIN Act, H.R.2617 - Consolidated Appropriations Act, 2023.
Elijah E. Cummings Lower Drug Costs Now Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing, health care cost and price transparency: HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act"; H.R.5801 - HELP Copays Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
NOPAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; S .586/H.R.3259 - NOPAIN Act, H.R.2617 - Consolidated Appropriations Act, 2023.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration; S. 2599/H.R. 4356 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022; Implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action."
United States Innovation and Competition Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities. Policies related to the reauthorization of the Prescription Drug User Fee Act. Policies related to the FDA in S. 1260, "US Innovation and Competition Act," and HR 4521, "America COMPETES Act." Issues related to platform technologies and other FDA-related provisions in S. 3799, "PREVENT Pandemics Act."
United States Innovation and Competition Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities; Policies related to the reauthorization of the Prescription Drug User Fee Act (H.R. 7667 and S. 4348); Policies related to the FDA in S. 1260 - "US Innovation and Competition Act" and H.R. 4521 - "America COMPETES Act"; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing, health care cost and price transparency: HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act"; H.R.5801 - HELP Copays Act.
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits (no specific bills). Issues related to the Orphan Drug Tax Credit. Issues related to corporate and international tax policy in HR 5376, "Build Back Better Act."
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - "Build Back Better Act."
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; H.Res. 1330 - Expressing support for the designation of September 2022 as "Sickle Cell Disease Awareness Month".
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; S .586/H.R.3259 - NOPAIN Act, H.R.2617 - Consolidated Appropriations Act, 2023.
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169).
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169).
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; H.Res. 1330 - Expressing support for the designation of September 2022 as "Sickle Cell Disease Awareness Month".
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; S .586/H.R.3259 - NOPAIN Act, H.R.2617 - Consolidated Appropriations Act, 2023.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing, health care cost and price transparency: HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act"; H.R.5801 - HELP Copays Act.
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
New Era of Preventing End-Stage Kidney Disease Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
New Era of Preventing End-Stage Kidney Disease Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; H.Res. 1330 - Expressing support for the designation of September 2022 as "Sickle Cell Disease Awareness Month".
New Era of Preventing End-Stage Kidney Disease Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; S .586/H.R.3259 - NOPAIN Act, H.R.2617 - Consolidated Appropriations Act, 2023.
Food and Drug Amendments of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Food and Drug Amendments of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities; Policies related to the reauthorization of the Prescription Drug User Fee Act (H.R. 7667 and S. 4348); Policies related to the FDA in S. 1260 - "US Innovation and Competition Act" and H.R. 4521 - "America COMPETES Act"; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Food and Drug Amendments of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.
Issues related to the Defense Health Agency and service member access to non-opioid alternatives, including reinstating the DHA Benefits Advisory Panel and the structured formulary management process.
Issues related to veteran's access to non-opioid alternatives and implementation of report language in the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (PL 119-37).
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Education about non-opioid pain therapies and patient access to non-opioid medicines, updates on coverage progress at the VHA and CMS.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Vice President of the U.S., White House Office
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2026 · second_quarter · Q2
Issues related to veteran's access to non-opioid alternatives and implementation of report language in the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (PL 119-37).
Issues related to Sec. 232 pharmaceutical tariffs, onshoring active pharmaceutical ingredients (API), and supply chain disruptions for products related to the opioid public health emergency.
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Education about non-opioid pain therapies and patient access to non-opioid medicines, updates on coverage progress at the VHA and CMS.
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
Issues related to the Defense Health Agency and service member access to non-opioid alternatives, including reinstating the DHA Benefits Advisory Panel and the structured formulary management process.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Vice President of the U.S., White House Office
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2026 · first_quarter · Q1
Education about non-opioid pain therapies and patient access to non-opioid medicines, updates on coverage progress at the VHA and CMS.
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
Intellectual property reforms to address unfair trade practices in Argentina and Russia.
Issues related to veteran's access to non-opioid alternatives and implementation of report language in the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (PL 119-37).
Issues related to the Defense Health Agency and service member access to non-opioid alternatives, including reinstating the DHA Benefits Advisory Panel and the structured formulary management process.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR), Vice President of the U.S., White House Office
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2025 · fourth_quarter · Q4
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
Education about non-opioid pain therapies and patient access to non-opioid medicines; Education on alternative funding programs; Education on the Million Veteran Program at the VA.
Intellectual property reforms to address unfair trade practices in Argentina and Russia.
Issues related to veteran's access to non-opioid alternatives and implementation of report language in the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (PL 119-37).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR), Vice President of the U.S., White House Office
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2025 · third_quarter · Q3
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, S.864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
Education about non-opioid pain therapies and patient access to non-opioid medicines; Education on alternative funding programs; Education on the Million Veteran Program at the VA.
Intellectual property reforms to address unfair trade practices in Argentina and Russia.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR), Vice President of the U.S., White House Office
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2025 · second_quarter · 2A
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, S.864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals; Issues regarding the One Big Beautiful Bill Act (PL 119-21).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2025 · second_quarter · Q2
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, S.864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals; Issues regarding the One Big Beautiful Bill Act (PL 119-21).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2025 · first_quarter · Q1
Unmet medical need in acute pain; H.R.1227/S.475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease.
Education about non-opioid pain therapies and patient access to non-opioid medicines, education on alternative funding programs, education on the Million Veteran Program at the VA.
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (S.864); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2024 · fourth_quarter · Q4
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Unmet medical need in acute pain; H.R.7421/S.3832 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2024 · third_quarter · Q3
Access to non-opioids in DoD/Tricare (H.R.8774/S.4921 - Department of Defense Appropriations Act, 2025); Access to non-opioids in VHA and general support for clinical trial operations at VHA to address high prevalence diseases and conditions (H.R.8580/S.4677 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025); Access to non-opioids for Medicare beneficiaries and education about risk of kidney disease amongst minority populations (H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025).
Unmet medical need in acute pain; H.R.7421/S.3832 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2024 · second_quarter · Q2
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2024 · first_quarter · Q1
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act.
Issues related to corporate and international tax policy and research and development tax credits, American Innovation and R&D Competitiveness Act (H.R. 2673) and American Innovation and Jobs Act (S. 866)
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2023 · fourth_quarter · Q4
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Implementation of P.L. 117-169 provisions related to Medicare prescription drugs; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program.
Issues related to corporate and international tax policy and research and development tax credits, American Innovation and R&D Competitiveness Act (H.R. 2673) and American Innovation and Jobs Act (S. 866)
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2023 · third_quarter · Q3
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Implementation of P.L. 117-169 provisions related to Medicare prescription drugs; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2023 · second_quarter · Q2
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (HR 830, S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs. Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2023 · first_quarter · Q1
Issues related to corporate and international tax policy and research and development tax credits.
Issues related to funding for the Food and Drug Administration - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act; General education about policies to improve outcomes for patients with APOL-1 kidney disease.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2022 · fourth_quarter · Q4
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2022 · third_quarter · Q3
Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.
Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2022 · second_quarter · Q2
Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - "Build Back Better Act."
Issues related to funding for the Food and Drug Administration; S. 2599/H.R. 4356 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022; Implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action."
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2022 · first_quarter · Q1
General education about FDA approval policies and NIH research activities. Policies related to the reauthorization of the Prescription Drug User Fee Act. Policies related to the FDA in S. 1260, "US Innovation and Competition Act," and HR 4521, "America COMPETES Act." Issues related to platform technologies and other FDA-related provisions in S. 3799, "PREVENT Pandemics Act."
Issues related to corporate and international tax policy and research and development tax credits (no specific bills). Issues related to the Orphan Drug Tax Credit. Issues related to corporate and international tax policy in HR 5376, "Build Back Better Act."
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2021 · fourth_quarter · Q4
Issues related to corporate and international tax policy and research and development tax credits (no specific bills). Issues related to the Orphan Drug Tax Credit. Issues related to corporate and international tax policy in HR 5376, "Build Back Better Act," and related provisions debated in Senate (no specific bill).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"); S Res 477, expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; HR 6000, "Cures 2.0"; and, Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act," and Senate companion legislation (no specific bill).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2021 · third_quarter · Q3
Issues related to corporate and international tax policy and research and development tax credits (no specific bills). Issues related to the Orphan Drug Tax Credit. Issues related to corporate and international tax policy in HR 5376, "Build Back Better Act."
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act."
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2021 · second_quarter · Q2
Issues related to corporate and international tax policy and research and development tax credits (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes."
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2021 · first_quarter · Q1
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to the development and application of gene and cell therapies (no specific bills); Issues related to health care cost and price transparency (no specific bills).
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2020 · fourth_quarter · 4A
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response and extension of health programs (H.R. 133, "Consolidated Appropriations Act, 2021").
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2020 · fourth_quarter · Q4
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response and extension of health programs (H.R. 133, "Consolidated Appropriations Act, 2021").
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2020 · third_quarter · Q3
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills). Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act" and HR 4712: "Fairness in Orphan Drug Exclusivity Act.").
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act"); Issues related to Administration actions on pharmaceutical pricing (no specific bills).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2020 · second_quarter · Q2
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills). Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act" and HR 4712: "Fairness in Orphan Drug Exclusivity Act.").
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act").
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2020 · first_quarter · Q1
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act").
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2019 · fourth_quarter · Q4
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: "More Efficient Tools to Realize Information for Consumers Act", and S. 1895: "Lower Health Care Costs Act").
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Education about non-opioid pain therapies and patient access to non-opioid medicines; Education on alternative funding programs; Education on the Million Veteran Program at the VA.
Intellectual property reforms to address unfair trade practices in Argentina and Russia.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
Education about non-opioid pain therapies and patient access to non-opioid medicines; Education on alternative funding programs; Education on the Million Veteran Program at the VA.
Intellectual property reforms to address unfair trade practices in Argentina and Russia.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, White House Office
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; Genetic kidney disease, including APOL-1; Ex-US access to innovative medicines; Cystic Fibrosis; Sickle cell disease.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Implementation of P.L. 117-169 provisions related to Medicare prescription drugs; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to funding for the Food and Drug Administration - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act; General education about policies to improve outcomes for patients with APOL-1 kidney disease.
Issues related to corporate and international tax policy and research and development tax credits, American Innovation and R&D Competitiveness Act (H.R. 2673) and American Innovation and Jobs Act (S. 866)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to corporate and international tax policy and research and development tax credits, American Innovation and R&D Competitiveness Act (H.R. 2673) and American Innovation and Jobs Act (S. 866)
Issues related to funding for the Food and Drug Administration - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act; General education about policies to improve outcomes for patients with APOL-1 kidney disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs. Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; S .586/H.R.3259 - NOPAIN Act, H.R.2617 - Consolidated Appropriations Act, 2023.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; H.Res. 1330 - Expressing support for the designation of September 2022 as "Sickle Cell Disease Awareness Month".
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
General education about FDA approval policies and NIH research activities; Policies related to the reauthorization of the Prescription Drug User Fee Act (H.R. 7667 and S. 4348); Policies related to the FDA in S. 1260 - "US Innovation and Competition Act" and H.R. 4521 - "America COMPETES Act"; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing, health care cost and price transparency: HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act"; H.R.5801 - HELP Copays Act.
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills). Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act").
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE